Suppr超能文献

通过CRISPR/Cas9基因编辑确定叔丁基对苯二酚、CDDO-Im和HO在人Jurkat T细胞中的Nrf2依赖性和非依赖性作用。

Nrf2-Dependent and -Independent Effects of -Butylhydroquinone, CDDO-Im, and HO in Human Jurkat T Cells as Determined by CRISPR/Cas9 Gene Editing.

作者信息

Zagorski Joseph W, Maser Tyler P, Liby Karen T, Rockwell Cheryl E

机构信息

Department of Pharmacology and Toxicology (J.W.Z., T.P.M., K.T.L., C.E.R.), Institute for Integrated Toxicology (J.W.Z., C.E.R.), and Cell and Molecular Biology Program (J.W.Z. C.E.R.), Michigan State University, East Lansing, Michigan.

Department of Pharmacology and Toxicology (J.W.Z., T.P.M., K.T.L., C.E.R.), Institute for Integrated Toxicology (J.W.Z., C.E.R.), and Cell and Molecular Biology Program (J.W.Z. C.E.R.), Michigan State University, East Lansing, Michigan

出版信息

J Pharmacol Exp Ther. 2017 May;361(2):259-267. doi: 10.1124/jpet.116.238899. Epub 2017 Mar 9.

Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a stress-activated transcription factor activated by stimuli such as electrophilic compounds and other reactive xenobiotics. Previously, we have shown that the commonly used food additive and Nrf2 activator -butylhydroquinone (tBHQ) suppresses interleukin-2 (IL-2) production, CD25 expression, and NFB activity in human Jurkat T cells. The purpose of the current studies was to determine whether these effects were dependent upon Nrf2 by developing a human Nrf2-null T cell model using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 technology. The current studies show that suppression of CD25 expression by tBHQ is partially dependent on Nrf2, whereas inhibition of IL-2 secretion is largely Nrf2-independent. Interestingly, tBHQ inhibited NFB activation in an Nrf2-independent manner. This was an unexpected finding since Nrf2 inhibits NFB activation in other models. These results led us to investigate another more potent Nrf2 activator, the synthetic triterpenoid 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im). Treatment of wild-type and Nrf2-null Jurkat T cells with CDDO-Im resulted in an Nrf2-dependent suppression of IL-2. Furthermore, susceptibility to reactive oxygen species was significantly enhanced in the Nrf2-null clones as determined by decreased mitochondrial membrane potential and cell viability. Importantly, this study is the first to describe the generation of a human Nrf2-null model, which is likely to have multiple applications in immunology and cancer biology. Collectively, this study demonstrates a role for Nrf2 in the effects of CDDO-Im on CD25 and IL-2 expression, whereas the effect of tBHQ on these parameters is complex and likely involves modulation of multiple stress-activated transcription factors, including NFB and Nrf2.

摘要

核因子红细胞2相关因子2(Nrf2)是一种应激激活的转录因子,可被亲电化合物和其他反应性外源性物质等刺激激活。此前,我们已经表明,常用的食品添加剂和Nrf2激活剂叔丁基对苯二酚(tBHQ)可抑制人Jurkat T细胞中白细胞介素-2(IL-2)的产生、CD25的表达以及NFκB的活性。本研究的目的是通过使用成簇规律间隔短回文重复序列(CRISPR)/CRISPR相关蛋白9技术构建人Nrf2基因敲除T细胞模型,来确定这些效应是否依赖于Nrf2。目前的研究表明,tBHQ对CD25表达的抑制部分依赖于Nrf2,而对IL-2分泌的抑制在很大程度上不依赖于Nrf2。有趣的是,tBHQ以不依赖于Nrf2的方式抑制NFκB的激活。这是一个出乎意料的发现,因为在其他模型中Nrf2会抑制NFκB的激活。这些结果促使我们研究另一种更有效的Nrf2激活剂,合成三萜类化合物1-[2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酰基]咪唑(CDDO-Im)。用CDDO-Im处理野生型和Nrf2基因敲除的Jurkat T细胞导致IL-2的Nrf2依赖性抑制。此外,通过线粒体膜电位降低和细胞活力测定,Nrf2基因敲除克隆对活性氧的敏感性显著增强。重要的是,本研究首次描述了人Nrf2基因敲除模型的构建,该模型可能在免疫学和癌症生物学中有多种应用。总的来说,本研究证明了Nrf2在CDDO-Im对CD25和IL-2表达的影响中起作用,而tBHQ对这些参数的影响是复杂的,可能涉及多种应激激活转录因子的调节,包括NFκB和Nrf2。

相似文献

2
Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation.
Biochem Pharmacol. 2018 Jan;147:67-76. doi: 10.1016/j.bcp.2017.11.005. Epub 2017 Nov 15.
3
The Nrf2 activator, tBHQ, differentially affects early events following stimulation of Jurkat cells.
Toxicol Sci. 2013 Nov;136(1):63-71. doi: 10.1093/toxsci/kft172. Epub 2013 Aug 14.
4
The Nrf2 activator tBHQ inhibits T cell activation of primary human CD4 T cells.
Cytokine. 2015 Feb;71(2):289-95. doi: 10.1016/j.cyto.2014.11.006. Epub 2014 Dec 5.
6
Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.
Eur J Pharmacol. 2009 Oct 12;620(1-3):138-44. doi: 10.1016/j.ejphar.2009.08.022. Epub 2009 Aug 19.
7
CDDO-Im ameliorates osteoarthritis and inhibits chondrocyte apoptosis in mice via enhancing Nrf2-dependent autophagy.
Acta Pharmacol Sin. 2022 Jul;43(7):1793-1802. doi: 10.1038/s41401-021-00782-6. Epub 2021 Nov 9.
10
CDDO-Me, Sulforaphane and tBHQ attenuate the RANKL-induced osteoclast differentiation via activating the NRF2-mediated antioxidant response.
Biochem Biophys Res Commun. 2019 Apr 9;511(3):637-643. doi: 10.1016/j.bbrc.2019.02.095. Epub 2019 Feb 27.

引用本文的文献

2
A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Mol Cancer Ther. 2021 Sep;20(9):1692-1701. doi: 10.1158/1535-7163.MCT-21-0210. Epub 2021 Jun 22.
4
Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.
Pharm Res. 2021 Feb;38(2):213-241. doi: 10.1007/s11095-021-02997-y. Epub 2021 Feb 22.
5
Nrf2-dependent and -independent effects of tBHQ in activated murine B cells.
Food Chem Toxicol. 2020 Nov;145:111595. doi: 10.1016/j.fct.2020.111595. Epub 2020 Jul 20.
6
Potential Applications of NRF2 Modulators in Cancer Therapy.
Antioxidants (Basel). 2020 Feb 25;9(3):193. doi: 10.3390/antiox9030193.
8
Nrf2 regulates CD4 T cell-induced acute graft-versus-host disease in mice.
Blood. 2018 Dec 27;132(26):2763-2774. doi: 10.1182/blood-2017-10-812941. Epub 2018 Oct 31.
9
Nitrolipids in kidney physiology and disease.
Nitric Oxide. 2018 Mar 29. doi: 10.1016/j.niox.2018.03.021.
10
Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes.
J Immunol. 2018 Mar 1;200(5):1929-1936. doi: 10.4049/jimmunol.1700812. Epub 2018 Jan 19.

本文引用的文献

1
The anti-inflammatory effects of E-α-(p-methoxyphenyl)-2',3,4,4'-tetramethoxychalcone are mediated via HO-1 induction.
Int Immunopharmacol. 2016 Jun;35:99-110. doi: 10.1016/j.intimp.2016.03.018. Epub 2016 Apr 16.
2
Applications of the CRISPR-Cas9 system in cancer biology.
Nat Rev Cancer. 2015 Jul;15(7):387-95. doi: 10.1038/nrc3950. Epub 2015 Jun 4.
3
The Nrf2 activator tBHQ inhibits T cell activation of primary human CD4 T cells.
Cytokine. 2015 Feb;71(2):289-95. doi: 10.1016/j.cyto.2014.11.006. Epub 2014 Dec 5.
6
Genome engineering using the CRISPR-Cas9 system.
Nat Protoc. 2013 Nov;8(11):2281-2308. doi: 10.1038/nprot.2013.143. Epub 2013 Oct 24.
7
Cas9 as a versatile tool for engineering biology.
Nat Methods. 2013 Oct;10(10):957-63. doi: 10.1038/nmeth.2649.
8
The Nrf2 activator, tBHQ, differentially affects early events following stimulation of Jurkat cells.
Toxicol Sci. 2013 Nov;136(1):63-71. doi: 10.1093/toxsci/kft172. Epub 2013 Aug 14.
9
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.
Cell. 2013 May 9;153(4):910-8. doi: 10.1016/j.cell.2013.04.025. Epub 2013 May 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验